ARBUTUS BIOPHARMA CORP (ABUS) Stock Price, Forecast & Analysis
USA - NASDAQ:ABUS - CA03879J1003 - Common Stock
ABUS Key Statistics, Chart & Performance
The current stock price of ABUS is 4.27 USD. In the past month the price decreased by -3.61%. In the past year, price increased by 21.65%.
ABUS Latest News, Press Relases and Analysis
ABUS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.65 | 411.45B | ||
| AMGN | AMGEN INC | 15.66 | 184.33B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 158.91B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.25 | 107.95B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 74.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.45 | 60.40B | ||
| INSM | INSMED INC | N/A | 43.03B | ||
| NTRA | NATERA INC | N/A | 29.97B | ||
| BIIB | BIOGEN INC | 10.03 | 24.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 21.55B | ||
| INCY | INCYTE CORP | 15.78 | 19.79B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 16.32B |
Related stock screener links
About ABUS
Company Profile
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, Pennsylvania and currently employs 44 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Company Info
ARBUTUS BIOPHARMA CORP
701 Veterans Circle
Warminster PENNSYLVANIA 18974 US
CEO: William H. Collier
Employees: 44
Phone: 16044193200
ARBUTUS BIOPHARMA CORP / ABUS FAQ
What does ARBUTUS BIOPHARMA CORP do?
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, Pennsylvania and currently employs 44 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Can you provide the latest stock price for ARBUTUS BIOPHARMA CORP?
The current stock price of ABUS is 4.27 USD. The price decreased by -4.04% in the last trading session.
What is the dividend status of ARBUTUS BIOPHARMA CORP?
ABUS does not pay a dividend.
What is the ChartMill rating of ARBUTUS BIOPHARMA CORP stock?
ABUS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Would investing in ARBUTUS BIOPHARMA CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ABUS.
What is the expected growth for ABUS stock?
The Revenue of ARBUTUS BIOPHARMA CORP (ABUS) is expected to grow by 132.92% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ARBUTUS BIOPHARMA CORP?
ARBUTUS BIOPHARMA CORP (ABUS) has a market capitalization of 818.56M USD. This makes ABUS a Small Cap stock.
ABUS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ABUS. When comparing the yearly performance of all stocks, ABUS is one of the better performing stocks in the market, outperforming 86.9% of all stocks.
ABUS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ABUS. ABUS has a great financial health rating, but its profitability evaluates not so good.
ABUS Financial Highlights
Over the last trailing twelve months ABUS reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 37.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.54% | ||
| ROE | -65.38% | ||
| Debt/Equity | 0 |
ABUS Forecast & Estimates
10 analysts have analysed ABUS and the average price target is 5.36 USD. This implies a price increase of 25.41% is expected in the next year compared to the current price of 4.27.
For the next year, analysts expect an EPS growth of 51.34% and a revenue growth 132.92% for ABUS